First Trust Advisors LP Sells 41,434 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

First Trust Advisors LP lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.5% in the third quarter, Holdings Channel.com reports. The institutional investor owned 210,383 shares of the biopharmaceutical company’s stock after selling 41,434 shares during the period. First Trust Advisors LP’s holdings in Alnylam Pharmaceuticals were worth $95,935,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Root Financial Partners LLC bought a new position in Alnylam Pharmaceuticals in the third quarter valued at about $25,000. Salomon & Ludwin LLC bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $27,000. Atlantic Union Bankshares Corp bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth about $30,000. ORG Partners LLC boosted its stake in shares of Alnylam Pharmaceuticals by 70.2% in the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 33 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter valued at approximately $36,000. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several brokerages recently issued reports on ALNY. Royal Bank Of Canada decreased their price target on shares of Alnylam Pharmaceuticals from $500.00 to $465.00 and set an “outperform” rating on the stock in a report on Tuesday, January 20th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Canaccord Genuity Group boosted their target price on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 17th. Finally, Needham & Company LLC dropped their price target on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $477.96.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY opened at $323.53 on Tuesday. The stock has a 50 day moving average of $350.74 and a 200 day moving average of $413.17. The company has a market capitalization of $42.91 billion, a price-to-earnings ratio of 189.20 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business’s quarterly revenue was up 84.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.65) EPS. As a group, sell-side analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the completion of the sale, the executive vice president owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares in the company, valued at approximately $28,452,215.46. This trade represents a 10.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last ninety days. Company insiders own 1.20% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.